@article{54777de6686340eb8d5c9d9e2e582e42,
title = "Mild Traumatic Brain Injury Is Related to Elevated Cerebrospinal Fluid Tau in Alzheimer's Disease Dementia",
abstract = "Few studies have examined an association between mild traumatic brain injury (mTBI) and Alzheimer's disease (AD). For this reason, we compared an AD dementia group with an mTBI history (n = 10) to a matched AD control group (n = 20) on measures of cognitive function, cerebral glucose metabolism, and markers of amyloid and tau deposition. Only a trend and medium-to-large effect size for higher phosphorylated and total tau was identified for the mTBI group. A history of mTBI may be associated with greater tau in AD, indicating a potential pathway for increasing risk for AD, though further evaluation with larger samples is needed.",
keywords = "Biomarkers, concussion, dementia, neurodegeneration, risk factor, tau formation, traumatic brain injury",
author = "Christian Lobue and Kelley, {Brendan J.} and John Hart and Jessica Helphrey and Jeff Schaffert and Cullum, {C. Munro} and Peters, {Matthew E.} and Douglas, {Peter M.}",
note = "Funding Information: Data collection and sharing for this project was funded by the Alzheimer{\textquoteright}s Disease Neuroimag-ing Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer{\textquoteright}s Association; Alzheimer{\textquoteright}s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujire-bio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Neu-roRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer{\textquoteright}s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Funding Information: While this study relied on well-matched groups and focused on mTBI, our study does have several limitations. These include a small sample size, potential for recall bias with injuries, lack of information regarding the criteria used by ADNI clinicians in recording a “concussion,” absence of tau-related genetic risk factors beyond APOE4, and a lack of diversity. Thus, this study serves as an important, This work was supported in part by an Alzheimer{\textquoteright}s Association Research Grant (2019-AARG643558) and the US Army Medical Research and Development Program (W81XWH-20-1-0493). Publisher Copyright: {\textcopyright} 2022 - IOS Press. All rights reserved.",
year = "2022",
doi = "10.3233/JAD-220112",
language = "English (US)",
volume = "87",
pages = "1491--1496",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",
}